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Abstract
Measuring virus-specific antibody responses to emerging pathogens is a well-established and highly useful tool
to  diagnose  such  infections,  understand  interactions  between  the  immune  system  and  pathogens,  and  provide
potential clues for the development of vaccines or therapeutic agents against such pathogens. Since the beginning
of  2020,  the  discovery  of  SARS-CoV-2  as  the  emerging  virus  responsible  for  the  COVID-19  pandemic  has
provided new insight into the complexity of antibody responses to this dangerous virus. The current review aims
to sort out diverse and sometimes seemingly confusing findings to put together a cohesive understanding on the
profile of antibody responses elicited in COVID-19 patients.
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Introduction
The human immune system mounts potent immune
responses when exposed to an emerging pathogen. On
one  hand,  such  immune  responses  can  lead  to
immunopathogenic  changes,  including  many  clinical
symptoms  such  as  those  observed  among  COVID-19
patients[1].  On  the  other  hand,  protective  or  acquired
immunity  can  be  developed  to  prevent  or  minimize
future  infection  by  the  same  pathogen.  Measuring
immune  biomarkers  such  as  specific  antibody
responses to emerging pathogens is a well-established
and highly useful  tool  to  diagnose such infections,  to
understand  interactions  between  the  immune  system
and  pathogens,  and  to  provide  potential  clues  for  the
development of vaccines or therapeutic agents against
such pathogens.
Since  the  beginning  of  2020,  the  discovery  of
SARS-CoV-2  as  the  emerging  virus  responsible  for
the  COVID-19  pandemic  has  provided  new  insight
into  the  complexity  of  antibody  responses  to  this
dangerous virus. This review will sort out diverse and
sometimes  seemingly  confusing  findings  to  put
together  a  cohesive  understanding  on  the  profile  of
antibody responses elicited in COVID-19 patients.
An  early  report  by  Zhou et  al established  a
milestone in detecting SARS-CoV-2 specific antibody
responses in COVID-19 patients[2]. They were the first
to  notice  that  while  this  virus  may  be  shed  through
multiple routes, the molecular diagnosis based on oral
swabs  could  only  detect  the  virus  in  about  50% of
COVID-19  cases.  In  contrast,  the  serology  tests  on
these  patients  were  almost  100% positive  (IgG  or
IgM).  An  increase  of  virus-specific  antibodies  in
nearly all patients was observed, with the IgM positive
rate increased from 50% to 81%, whereas IgG positive
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rate increased from 81% to 100% by day 5 of SARS-
CoV-2 infection.
This  first  report  only  included  samples  from  16
patients,  but  it  is  important  to  show  that  serology
testing  can  greatly  improve  positive  detection  of
SARS-CoV-2  infections,  and  thus  should  be  used  in
both  clinical  practice  and  epidemiological
investigations.
Antibodies to nucleocapsid vs. spike proteins
of SARS-CoV-2 in COVID-19 patients
It  is  well  known from classical  coronavirus studies
that  two  key  viral  structural  proteins,  spike  (S)  and
nucleocapsid  (N),  are  main  targets  of  antibody
responses  after  infection  by  coronaviruses.  The  S
protein is  responsible  for  virion attachment  and entry
into  host  cells  by  mediating  interaction  with  cell
receptor and membrane fusion, whereas the N protein
is  involved in  virion  assembly,  playing  a  pivotal  role
in  virus  transcription  and  assembly  efficiency.  The
development  of  antibodies  to  these  two  proteins  may
have  different  time  course  and  these  antibodies  may
serve different biological functions.
Ling Chen and his group investigated both IgM and
IgG  forms  of  antibody  responses  against  N  and  S
proteins after the symptom onset among intensive care
unit  (ICU)  and  non-ICU  patients[3].  Both  N  and  S-
specific  IgM and IgG responses increased along with
disease course in non-ICU patients, detectable among
75% of patients in the first week and reaching 94.7%
and 100% respectively in the second and third weeks
after  symptom  onset,  while  dynamic  patterns  for
SARS-CoV-2  specific  antibody  responses  (no  matter
N  or  S,  IgM  or  IgG)  were  more  "chaotic",  or  not
having  a  clear  pattern,  in  ICU patients.  These  results
further  demonstrate  that  the combined detection of  N
and  S-  specific  IgM  and  IgG  antibodies  can  increase
the  positive  rate  of  COVID-19  diagnosis,  so  such  an
approach may be useful for early detection of SARS-
CoV-2 infections.
When  antibody  kinetics  were  analyzed  in  a
subgroup  of  physicians  with  PCR-confirmed
infections  and  mild  to  moderate  symptoms,  quite
different  kinetic  patterns  were  observed  for  the
appearance of IgG and IgA antibodies against SARS-
CoV-2  S1  protein[4].  A  significant  increase  and  high
detection rate of SARS-CoV-2-specific IgG antibodies
was  only  found  around  the  third  week  (29% at  the
second week and 94% at  the third week after  disease
onset),  while  positive  serum  IgA  antibodies  were
detected early in all individuals. One study participant
with  an  absence  of  IgG  antibodies  showed  a  highly
positive  IgA  antibody  level  in  the  second  week  after
symptom onset.
Due  to  the  highly  transmissible  nature  of  COVID-
19,  timely  diagnosis  and  management  of  COVID-19
patients  is  essential.  Two  more  reports  further
highlighted the importance of serology testing for the
confirmation  of  COVID-19.  In  one  study,  N  and  S
antigen-based  serology  testing  showed  IgM-positive
results  for  SARS-CoV-2  among  32.0% of  clinically
confirmed  but  RT-qPCR  negative  patients  who  were
already  4 –14  days  after  symptom  onset[5].  Another
report  is  from  a  family  cluster  of  SARS-CoV-2
infections.  Five  of  six  family  members  were  positive
for  SARS-CoV-2  specific  immunoglobins  with
serology testing, while molecular assays only detected
viruses in two of these five patients,  even when done
twice[6].
As  SARS-CoV  is  genetically  related  to  SARS-
CoV-2,  sharing  approximately  80% gene  sequence
identity,  one concern is if  a cross-reactivity exists for
COVID-19  antibody  tests  between  two  viruses.  One
comprehensive  comparison  between  COVID-19  and
SARS  patient  sera  was  conducted  by  Lin-Fa  Wang
and  his  colleagues[7].  Their  results  show a  significant
cross-reactivity  when  the  N  protein  of  either  virus  is
used, which is not unexpected, as the N protein shares
higher  homology  between  the  two  viruses.  At  the
same time, the S1 or receptor-binding domain (RBD)
of the S protein offers better specificity. Interestingly,
anti-N  antibodies  against  SARS  virus  waned  more
quickly than anti-RBD antibodies 17 years after SARS
infection.  Consistent  with  high  specificity  of  S1  or
RBD,  two  studies  demonstrated  that  there  is  no
detectable  cross-neutralization  by  SARS  patient  sera
against SARS-CoV-2[8–9].
Kinetics  of  IgM  and  IgG  responses  in
COVID-19 patients
It is textbook teaching that IgM antibodies indicate
early-stage  responses  during  viral  infections  prior  to
the  development  of  the  class-switched,  high-affinity
IgG  responses  which  are  the  basis  for  long-term
immunity  and  immunological  memory.  Similar
patterns  of  IgM  and  IgG  antibody  responses  in
COVID-19  patients  were  observed:  1)  the  IgM
antibody  responses  to  SARS-CoV-2  occurred  earlier
than IgG antibody responses (IgM from day 4 onward
vs. IgG  from  day  7  onward)  and  IgM  antibody
responses  peaked  earlier  than  the  IgG  antibody
responses  (IgM  at  day  20 vs. IgG  at  day  25);  2)  the
IgM antibody response began to decline at week 3 of
the  illness,  but  the  IgG  antibody  response  persisted
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and  was  maintained  at  high  levels  in  patients  with
COVID-19,  at  least  during  the  one-month  time  of
reported  studies;  and  3)  severe  cases  of  COVID-19
had  a  more  vigorous  response  in  both  IgG  and  IgM
antibodies than less severe cases[10].
However, certain reports showed some patients had
earlier seroconversion for IgG than IgM against either
N proteins (IgG 26% vs. IgM 4%) or RBD (IgG 57%
vs. IgM 4%)[11]. More detailed analysis even suggested
that  there  are  three  types  of  seroconversions:
synchronous  seroconversion  of  IgG  and  IgM,  IgM
seroconversion  earlier  than  that  of  IgG,  and  IgM
seroconversion later than that of IgG[12]. It is not clear
why  the  timing  of  IgM and  IgG antibody  occurrence
vary among different studies, but it may be associated
with age as well as comorbidity[11].
Mild vs. severe cases, and intensive care unit
(ICU) vs. non-ICU cases
COVID-19 has a wide spectrum of disease severity,
from  mild  upper  respiratory  symptoms  to  respiratory
failure. Many studies have been conducted to analyze
antibody  titers  and  the  temporal  profiles  among
patients  with  different  disease  severity.  The  overall
theme is that more severe cases have higher antibody
responses.
Long et al reported higher IgG and IgM titers in the
severe  group  than  those  in  the  non-severe  group,
although  a  significant  difference  was  only  observed
for IgG titers at  the 2-week post-symptom onset time
point[12].  It  was  observed  that  there  was  a  delayed
specific  IgM  antibody  response  among  COVID-19
patients  with  severe  disease  progression[5].  Another
study  confirmed  an  early  induction  of  antibody
responses in severe cases than in mild cases, which led
to a speculation that  high level of SARS-CoV-2 viral
load  in  severe  cases  may  drive  an  early  antibody
response  caused  by  immediate  activation  of
extrafollicular B cells during acute infection[13]. Such a
high  quantity  of  antibodies  can  contribute  greatly  to
inflammatory  responses  by  promoting  monocyte  and
macrophage  accumulation  and  the  massive  cytokine
storm  including  IL-8  and  MCP-1,  and  might  be
responsible for fatal acute lung injury, as found during
SARS-CoV-2 infection.
In the same study conducted by Ling Chen and his
colleagues, it was observed that most ICU patients had
higher  N-IgG  than  S-IgG  levels  after  the  symptom
onset[3],  which  may  be  caused  by  longer  and  higher
amounts  of  virus  exposure  in  the  early  infections  of
ICU patients.  S-IgG levels  in  ICU patients  were  also
significantly  lower  than  in  non-ICU  patients  by  2
weeks  after  the  onset  of  symptoms,  which  may
explain  the  longer  hospital  stays  and  longer  duration
of  nucleic  acid-positive  days  in  ICU  patients.  They
concluded  that  monitoring  the  kinetics  of  S-IgG
should help to predict prognosis.
Regular  antibodies vs. neutralizing
antibodies
Knowledge  regarding  the  neutralizing  antibody
(NAb)  response  for  COVID-19  patients  is  critical  to
understanding  the  host  humoral  immune  response
towards  SARS-CoV-2  and  the  pathogenesis  of
COVID-19.  Questions  such  as  the  kinetics  of  SARS-
CoV-2  specific  NAb  development  during  the  course
of  disease,  the  role  of  NAbs  on  disease  progression,
and  the  variability  of  NAb  titers  among  different
patients such as elderly vs. young and mild vs. severe
cases offer significant importance.
A  cohort  study  of  175  recovered  COVID-19
patients  who  experienced  mild  symptoms  shows  that
SARS-CoV- 2 specific NAbs were detected in patients
from  day  10 –15  from  the  onset  of  the  disease  and
remained  at  least  to  day  28[8].  The  titers  of  NAb
among these patients correlated with the spike-binding
antibodies  targeting  S1,  RBD,  and  S2  regions,  which
indicated  that  in  addition  to  the  RBD  region,  S2
domain  might  also  be  the  target  of  SARS-CoV-2
NAbs as originally reported for study of S2 region of
SARS  virus[14].  From  the  same  study,  the  titers  of
NAbs  were  found  to  be  variable  for  different  age
groups.  Elderly  and  middle-age  patients  had
significantly  higher  plasma  NAb  titers  and  spike-
binding  antibodies  than  young  patients.  The  NAb
titers  were  positively  correlated  with  plasma  CRP
levels  but  negatively  correlated  with  the  lymphocyte
counts  of  patients,  suggesting  that  the  humoral
response  might  play  an  important  role  when  cellular
response was dysfunctional or impaired.
The  variability  of  NAb  titers  was  also  studied
among  ICU  patients vs. non-ICU  patients[15].  ICU
patients  had  an  accelerated  and  augmented  NAb
response  compared  to  non-ICU  patients,  which  was
associated with  disease severity.  Oxygen requirement
and  fever  during  admission  were  the  only  clinical
factors  independently  associated  with  higher  NAb
titers  based  on  multivariate  analysis.  In  this  report,
authors  also  discussed  why  the  faster  NAb  response
did not  ameliorate  the severe disease.  First,  there can
be  overwhelming  virus-induced  damage  in  the  lungs,
which  exacerbates  proinflammatory  cytokine
response.  Second,  high  NAb  titer  in  ICU  patients
might be due to higher viral/antigen loads during acute
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SARS-CoV-2  infection.  High  viral  load  and  rapid
antibody  development  could  enhance  macrophage-
mediated  acute  lung  injury[11,13].  Third,  anti-spike
protein antibodies, which contain potent RBD-specific
NAb,  can  worsen  disease  by  skewing  macrophage
responses during acute SARS-CoV infection[16].
Consistent  with  the  above  results,  a  new  study
examined SARS-CoV-2 neutralizing antibodies in the
plasma of patients with different disease severity. This
study shows that  patients with severe COVID-19 had
more  robust  binding  antibodies  to  both  N  and  S
trimers.  Functionally  active  antibodies  capable  of
virus  neutralization  were  also  more  abundant  (5 –7-
fold higher) in the patients with severe infections[17].
One  study  investigated  the  relationship  between
viral  shedding  and  SARS-CoV-2-specific  NAb  in
children with COVID-19[18]. Among the eight patients
in  the  acute  phase  (1 –4  days  after  illness  onset),
NAbs  were  produced  in  the  sera  of  three  patients
(50% inhibitory concentration [IC50]>80). All patients
then  produced  medium  to  high  NAb  titers  in  the
convalescent  phase  (IC50>500)  except  in  one  case
(IC50=307.2).  This  finding  indicated  that  children  do
develop  a  robust  NAb  response  after  SARS-CoV-2
infection,  and  humoral  immunity  may  play  a  more
critical  role  in  the  recovery  of  pediatric  patients  than
in that of adult patients.
Unique  situation:  antibodies  in  maternal
milk
As the COVID-19 outbreak further progressing to a
pandemic,  the  number  of  pregnant  women  and
neonates affected by SARS-Cov-2 is also on the rise[19].
Understanding  the  viral  loads  and  antibody  titers  of
SARS-Cov-2  in  maternal  women  and  neonates  is
important  to  reduce  the  risks  of  SARS-CoV-2
infection  of  neonates,  and  further  transmission  to
others  with  close  contact.  One  study  examining  this
followed the viral loads and antibody titers to SARS-
CoV-2  in  a  maternal  woman  and  the  neonate  during
their  hospital  stay[20].  The  mother  was  positive  for
SARS-CoV-2  tested  in  throat  swabs  but  negative  in
other  body fluids,  and  she  had  IgG and  IgA detected
in  breast  milk.  Her  infant  was  negative  for  SARS-
CoV-2  at  birth  but  had  elevated  IgG  in  serum  and
quickly  came  down  to  baseline.  These  findings
suggest that breastfeeding might have potential benefit
to the neonates.
Factors  affecting  the  accurate  serological
measurements of COVID-19 patients
Accurate  and  rapid  diagnosis  is  critical  for
achieving  control  of  COVID-19.  Molecular  biology
based  testing  such  as  reverse  transcriptase  PCR  is
widely  used  for  diagnosis  of  COVID-19;  however,
limitations  including  potential  false  negative  or  false
positive  results  have  greatly  reduced  its  potential
utility  and  another  complementary  diagnostic
approach  is  needed.  Serological  tests  have  generated
substantial interest and have been already used widely.
However,  the  accuracy  of  serological  tests  can  vary
dramatically depending a number of variables.
As  discussed  in  the  above  sections,  the  choice  of
detecting  antigens  is  the  first  priority  in  studying  the
serology  responses  in  COVID-19  patients.  Certain
coronaviral  proteins  may  have  a  higher  chance  of
cross-reactivity  than  others.  People  living  in  certain
endemic  areas  with  non-severe,  classical
coronaviruses may have higher prevalence of positive
serology to  these  viruses  and thus  a  higher  chance to
cross-react  with  the  emerging  SARS-CoV-2.  Studies
have  reported  that  the  serological  cross-reactivity
between  COVID-19  and  other  coronavirus  diseases
like  SARS-CoV  seem  to  be  high  with  the  N
protein[7]. While the data so far indicates that S protein
from  SARS-CoV-2  is  quite  specific  to  SARS-CoV-2
infection,  the  high  level  production  of  S  protein  has
been proven very difficult.  The companies limited by
the  lack  of  S  protein  supply  may  seek  other  viral
proteins  for  serology  test.  Without  adequate  research
and  development  working  using  enough  COVID-19
patient sera to validate the assay, such serology testing
kits may generate more false positive results.
Next, the reagents needed to detect IgM or IgG may
have  different  quality  control  issues.  Secondary  anti-
IgM or  anti-IgG  antibodies  may  come  from different
animal  sources  (goat,  rabbit,  or  other  animal  hosts)
with  different  specificity  and  affinity.  The  testing
method can also greatly affect the final assay readings
including  commonly  used  enzyme  linked
immunosorbent  assays  (ELISAs),  lateral  flow
immunoassays  (LFIAs),  or  chemiluminescent
immunoassays (CLIAs)[21–23].  The point-of-care (PoC)
test and ELISA conducted in an experienced research
lab clearly will have different controls and cut-offs.
Finally,  study  populations  (age,  sex,  clinical
severity)  and  the  timing  of  specimen  collection  in
relation  to  onset  of  symptoms  will  also  affect  the
scoring  of  positive  serology[3–5,10].  A  meta-analysis
conducted  by  the  team  led  by  Yi-Wei  Tang  and
Wenhong  Zhang  evaluated  published  cohort  studies
for  the  diagnostic  efficacy  and  characteristics  of  the
current serological tests for COVID-19[23]. Their result
concluded  that  serology  tests  had  the  lowest
sensitivity  at  0 –7  days  after  symptom  onset,  but  the
highest  at >14  days.  Total  antibody  (both  IgG  and
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IgM),  using  combined  N  and  S  proteins  had  a  better
sensitivity compared to N or S protein only. Colloidal
gold-immunochromatography  assay  and  LFIA  had  a
lower sensitivity than ELISA and CLIA. PoC tests had
a lower sensitivity than non-PoC tests. One limitation
that  they  point  to  is  the  lack  of  cross-
reactivity/specificity  analysis  due  to  the  limitation  of
data  extraction,  where  most  qualified  articles  did  not
provide such data.
Summary
Overall the serology responses in COVID-19 cases
fit  the  classical  literature  on  an  emerging  viral
infection, but there are a few unique findings.
● Both S protein and N protein can be the target for
antibody  responses,  but  N  protein  may  have  higher
chance  to  have  cross-reactivity  with  other
coronaviruses.
● Both IgM and IgG responses are detectable early
in  infection  with  IgM  responses  being  detectable  a
little  earlier  than  IgG  responses.  As  in  other  viral
infections, IgG is more persistent than IgM.
●  Severe  cases  may  paradoxically  have  early  and
high level S and N specific antibodies, including NAb.
Such  antibodies  may  be  the  responses  to  a  more
severe  infection  due  to  higher  viral  load  or  stronger
immune  responses.  Such  finding  in  severe  cases
should  not  be  extrapolated  to  conclude  that  anti-S
antibodies or NAbs are the "cause" of severe diseases.
● The same findings between mild and severe cases
are also observed between non-ICU and ICU patients,
reflecting  the  same  virology  and  immunology
mechanisms.
●  Short-lived  antibody  responses  were  seen  in
many recovered COVID-19 patients (either mild cases
or  non-ICU  patients)  who  had  a  relatively  low  viral
load infection, mainly at the respiratory track, without
experiencing  viremia.  In  these  cases  the  body's
immune response  was  able  to  clear  the  virus,  but  the
immunity  may  be  local  and  mucosal  site  based.  The
immunogenicity of such infection is relatively low and
may  not  lead  to  a  long  lasting  systemic  immune
response.
●  The  positive  serology  responses  in  COVID-19
patients  confirms  that  SARS-CoV-2  infection  can
stimulate  the  body's  protective  immunity  with
detectable  antibody  responses.  While  the  antibody
response may not be long-persisting in some patients,
this  finding  does  not  in  any  way  deny  the  chance  of
vaccine development against COVID-19. It only states
that  the  immune  protection  elicited  by  vaccines  need
to be much stronger than those observed in mild cases
of COVID-19 patients.
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